Moreover, along with an increased risk of toxicity, a phase 2 study demonstrated that pembrolizumab lacked efficacy in EGFR-mutant, PD-L1-positive, and TKI-naive patients with advanced NSCLC, including those with PD-L1 ≥50% (32). Here, EGFR is linked to non-small cell lung carcinoma.